Alterity Therapeutics Ltd
Alterity Therapeutics Ltd is a biotechnology company focused on the development of novel therapeutics for the treatment of chronic diseases, primarily generating revenue through research and development activities and partnerships.
Business. Alterity Therapeutics Ltd (ATHE.O) is a biotechnology and medical research company operating within the healthcare diagnostics industry. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Alterity Therapeutics Ltd (ATHE.O) is a biotechnology and medical research company operating within the healthcare diagnostics industry. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Alterity Therapeutics has a strong liquidity position, with a current ratio of 12.98 and cash and equivalents amounting to 33,158,640 AUD, indicating a robust ability to meet short-term obligations. The company's price-to-book ratio of 2.0 and price-to-tangible-book ratio of 2.0 suggest that the market values the company at twice its book value, which is relatively high compared to industry norms.
The company's profitability is currently negative, with a return on equity of -28.65% and a return on assets of -26.39%, indicating that it is not generating returns for its shareholders or effectively utilizing its assets. These metrics are significantly below the industry median, highlighting the challenges Alterity faces in achieving profitability.
Alterity Therapeutics does not disclose specific segments or geographic regions contributing to its revenue, making it difficult to assess revenue concentration. However, the company's operations are primarily based in Australia, and it is likely that a significant portion of its revenue is generated domestically.
The company's growth trajectory is uncertain, with no clear indication of revenue growth in the current or next fiscal year. The absence of capital expenditures and the negative operating and free cash flows suggest that the company is in a development phase, relying on existing cash reserves rather than generating positive cash flows.
The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's debt-to-equity ratio of 0.0 suggests that it is not leveraging debt to finance its operations, which reduces financial risk. However, the negative net income and operating income highlight the operational risks the company faces.
Recent events and filings do not indicate any significant changes in the company's financial or operational status. The company continues to focus on research and development, with no major partnerships or product launches reported in the latest financial data.
- Alterity Therapeutics has a strong liquidity position with a current ratio of 12.98 and significant cash reserves.
- The company is not currently profitable, with a return on equity of -28.65% and a return on assets of -26.39%.
- The company's valuation is high relative to its book value, with a price-to-book ratio of 2.0.
- There is no clear indication of revenue growth in the current or next fiscal year.
- The company faces operational risks due to negative net income and operating income.
- The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected.
- **margin_outlook_rationale**: The company's margin outlook is negative due to the current negative return on equity and return on assets.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,82 |
| Revenue | —no estimate | —no estimate | 1,1M AUD |
| Operating income | —no estimate | —no estimate | -8,6M AUD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- Director · Unlisted option exp 15 Jun 2031 → Ordinary sharesAcquired 2 000 000 @ $1,00grant · 2026-06-15
- Director · Listed option exp 15 Jun 2031 → Ordinary sharesAcquired 1 000 000 @ $1,00grant · 2026-06-15
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- Alterity Therapeutics Ltd Market data — financials · 2026-05-27
- Alterity Therapeutics Ltd Market data — analyst estimates · 2026-05-27
- Alterity Therapeutics Ltd Market data — ESG · 2026-05-27
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M